ProMIS Neurosciences Inc.
Datakwaliteit: 83%
PMN
Nasdaq
Manufacturing
Chemicals
€ 12,07
▲
€ 1,37
(12,80%)
Marktkapitalisatie: 108,24 M
Prijs
€ 12,07
Marktkapitalisatie
108,24 M
Dagbereik
€ 11,25 — € 12,77
52-Weeksbereik
€ 6,27 — € 39,75
Volume
44.317
Openen € 11,25
50D / 200D Gem.
€ 16,65
27,50% below
50D / 200D Gem.
€ 12,77
5,49% below
Quick Summary
Belangrijkste Punten
Earnings declined -1529,33% over the past year
Negative free cash flow of -28,12 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)-1529,33%
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-902,22%
Onder sectorgemiddelde (-53,47%)
ROIC-710,49%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio1,76
Interest CoverageN/A
Waardering
PE (TTM)
-2,73
Onder sectorgemiddelde (-1,47)
P/B Ratio11,78
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -2,7 | -1,5 |
| P/B | 11,8 | 1,6 |
| ROE % | -902,2 | -53,5 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
ETFs Holding This Stock
TBGVX
TBGVX
0,77% weight
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | -1529,33% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -39,72 M |
| ROE | -902,22% | ROA | -256,52% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -28,12 M |
| ROIC | -710,49% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 1,76 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 9,25 M | Tangible Book Value | 9,19 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -2,73 | Forward P/E | N/A |
| P/B Ratio | 11,78 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -25,98% | ||
| Market Cap | 108,24 M | Enterprise Value | 92,84 M |
| Per Share | |||
| EPS (Diluted TTM) | -22,61 | Revenue / Share | N/A |
| FCF / Share | -3,14 | OCF / Share | -3,14 |
| EPS CAGR (1Y) | -20654,55% | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 70,79% |
| SBC-Adj. FCF | -28,89 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Net Income | -39,72 M | 2,78 M | -13,21 M | -18,06 M |
| EPS (Diluted) | -22,61 | 0,11 | -1,07 | -2,41 |
| Gross Profit | — | — | — | — |
| Operating Income | -40,17 M | -16,83 M | -14,26 M | -23,38 M |
| EBITDA | — | — | — | — |
| R&D Expenses | 33,38 M | 10,64 M | 7,88 M | 16,09 M |
| SG&A Expenses | — | — | — | — |
| D&A | — | — | — | — |
| Interest Expense | — | — | 282.064,0 | 282.064,0 |
| Income Tax | — | 0,0 | 0,0 | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Total Assets | 9,18 M | 18,91 M | 13,62 M | 6,92 M |
| Total Liabilities | 10,44 M | 2,42 M | 9,87 M | 8,27 M |
| Shareholders' Equity | -1,26 M | 16,49 M | 3,75 M | -1,35 M |
| Total Debt | — | — | 0,0 | 3,91 M |
| Cash & Equivalents | 6,12 M | 13,29 M | 12,60 M | 5,88 M |
| Current Assets | 9,18 M | 18,91 M | 13,62 M | 6,90 M |
| Current Liabilities | 10,41 M | 2,22 M | 9,35 M | 6,41 M |
{"event":"ticker_viewed","properties":{"ticker":"PMN","listing_kind":"stock","pathname":"/stocks/pmn","exchange":"Nasdaq","country":"US"}}